In Russia, a decrease in the volume of release into civilian circulation of the drug “Effient” from Eli Lilly, used to prevent recurrent heart attacks, has been recorded. Vedomosti writes about this with reference to a representative of the Ministry of Health.
He did not mention the reasons for the shortage, but said that Roszdravnadzor had not received information about the cessation of supplies from the manufacturer. The head of the Zdravcity pharmaceutical market, Boris Popov, said that Effient’s official distributor in Russia, Servier The company notified its partners that supplies of the drug to the country were suspended in September 2023 and there are no plans to resume them.
American Eli Lilly stopped investing in the Russian Federation and also canceled new clinical trials in March 2022 as part of anti-Russian sanctions. In addition, the manufacturer has suspended the supply of non-essential medicines to the country. In March 2023, Eli Lilly decided to transfer the Russian business to the Swiss Swixx Biopharma.
Author:
Karina Pardaeva
Source: RB
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
